A Therapeutic Antigen-Presenting Cell-Targeting DNA Vaccine VB10.16 in HPV16-Positive High-Grade Cervical Intraepithelial Neoplasia: Results from a Phase I/IIa Trial.

Peter Hillemanns Agnieszka Denecke Linn Woelber Gerd Böhmer Matthias Jentschke Karoline W Schjetne Karsten M H Bruins Slot Agnete B Fredriksen

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

The novel therapeutic DNA vaccine VB10.16 was well tolerated and showed promising evidence of efficacy and strong HPV16-specific T-cell responses in subjects with high-grade CIN.

Keyphrases

high grade
low grade
circulating tumor
cell free
single molecule
single cell
clinical trial
study protocol
cell therapy
cancer therapy
randomized controlled trial
phase ii
mesenchymal stem cells
double blind
cervical cancer screening